Learn how molecular technology is enhancing patient safety for CAR-T clinical trials.

US FDA recently initiated class safety labeling changes after evaluating the safety of CAR-T cancer treatment therapies. What does this mean for developers in the CAR-T landscape? Listen to your free podcast to find out.

Listen in on the conversation as experts from Cerba discuss facilitating patient safety measures in CAR-T therapies by accurately identifying the integration of viral vectors, utilizing flow cytometry, and more.

Listen now as experts discuss answers to:

· What patient monitoring is required by the FDA?

· What molecular technology does Cerba use and how does it meet FDA requirements?

· What is the importance of cytometry assays in monitoring CAR-T cells?

· What are the opportunities for combining flow cytometry with genomic solutions?

· What key innovations are poised to improve patient monitoring in clinical trials?